Paul Vigano Sells 1,000,000 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Paul Vigano sold 1,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $8.00, for a total transaction of $8,000,000.00. Following the sale, the insider owned 245,251 shares in the company, valued at $1,962,008. This represents a 80.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Aveanna Healthcare Trading Up 1.9%

Aveanna Healthcare stock opened at $8.64 on Friday. The company has a 50 day moving average price of $7.14 and a 200 day moving average price of $7.58. Aveanna Healthcare Holdings Inc. has a 52 week low of $3.73 and a 52 week high of $10.32. The company has a debt-to-equity ratio of 5.35, a quick ratio of 1.47 and a current ratio of 1.47. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 7.32, a P/E/G ratio of 0.89 and a beta of 1.93.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.05. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The firm had revenue of $647.91 million for the quarter, compared to analysts’ expectations of $613.22 million. Aveanna Healthcare’s revenue was up 15.9% on a year-over-year basis. Research analysts forecast that Aveanna Healthcare Holdings Inc. will post 0.65 EPS for the current year.

Institutional Trading of Aveanna Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of AVAH. AustralianSuper Pty Ltd purchased a new position in Aveanna Healthcare in the third quarter valued at about $15,743,000. Vanguard Group Inc. raised its stake in shares of Aveanna Healthcare by 38.0% during the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after purchasing an additional 1,535,351 shares in the last quarter. Algert Global LLC lifted its holdings in shares of Aveanna Healthcare by 120.1% during the 3rd quarter. Algert Global LLC now owns 1,022,599 shares of the company’s stock valued at $9,070,000 after buying an additional 557,898 shares during the last quarter. Quantbot Technologies LP lifted its holdings in shares of Aveanna Healthcare by 1,220.8% during the 3rd quarter. Quantbot Technologies LP now owns 109,707 shares of the company’s stock valued at $973,000 after buying an additional 101,401 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of Aveanna Healthcare by 149.4% in the 4th quarter. UBS Group AG now owns 394,182 shares of the company’s stock valued at $3,220,000 after buying an additional 236,152 shares in the last quarter. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research report on Friday, March 20th. Stephens upgraded Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Weiss Ratings cut Aveanna Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Truist Financial upped their target price on Aveanna Healthcare from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 20th. Finally, Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price target for the company in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.50.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.